Janus Henderson Group
BNTC icon

Janus Henderson Group’s Benitec Biopharma BNTC Stock Holding History

Janus Henderson Group’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$30.7M Sell
2,876,380
-35,308
-1% -$409K 0.01% 514
2025
Q4 		$39.3M Hold
2,911,688
– – 0.02% 459
2025
Q3 		$40.7M Buy
2,911,688
+8,894
+0.3% +$114K 0.02% 455
2025
Q2 		$33.8M Sell
2,902,794
-16,156
-0.6% -$226K 0.02% 469
2025
Q1 		$39M Buy
2,918,950
+302,523
+12% +$3.66M 0.02% 430
2024
Q4 		$33.3M Buy
2,616,427
+1,739,904
+199% +$18.8M 0.02% 476
2024
Q3 		$8.03M Sell
876,523
-24,293
-3% -$217K ﹤0.01% 736
2024
Q2 		$6.19M Buy
900,816
+656,325
+268% +$4.84M ﹤0.01% 772
2024
Q1 		$1.27M Buy
244,491
+64,092
+36% +$246K ﹤0.01% 1516
2023
Q4 		$589K Sell
180,399
-25,771
-12% -$86K ﹤0.01% 1912
2023
Q3 		$631K Buy
+206,170
New +$641K ﹤0.01% 1813

Other funds holding BNTC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Janus Henderson Group's BNTC Position: Q1 2026 in Review

Janus Henderson Group reduced its Benitec Biopharma (BNTC) stake by 1.2% in Q1 2026, selling an estimated $409K and leaving 2,876,380 shares worth $30.7M. The position accounts for 0.01% of the portfolio, ranked #514.

Janus Henderson Group first reported a position in BNTC in Q3 2023 and has held it in 11 quarters since. The position peaked at $40.7M in Q3 2025. 88 funds tracked by Wall St. Rank hold BNTC as of Q1 2026.

  • Janus Henderson Group held 2,876,380 shares of Benitec Biopharma worth $30.7M as of Q1 2026.
  • Janus Henderson Group sold 35,308 Benitec Biopharma shares in Q1 2026, an estimated $409K.
  • Benitec Biopharma made up 0.01% of Janus Henderson Group's portfolio in Q1 2026, its #514 holding.
  • Janus Henderson Group first reported a position in Benitec Biopharma in Q3 2023 and has held it in 11 quarters since.
  • Janus Henderson Group's Benitec Biopharma position peaked at $40.7M in Q3 2025.
  • 88 funds tracked by Wall St. Rank held Benitec Biopharma as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.